ALPMF (Astellas Pharma) Accounts Payable & Accrued Expense : $1,492 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Accounts Payable & Accrued Expense?

Astellas Pharma's quarterly accounts payable & accrued expense increased from Sep. 2024 ($1,380 Mil) to Dec. 2024 ($1,602 Mil) but then declined from Dec. 2024 ($1,602 Mil) to Mar. 2025 ($1,492 Mil).

Astellas Pharma's annual accounts payable & accrued expense increased from Mar. 2023 ($1,088 Mil) to Mar. 2024 ($1,493 Mil) but then declined from Mar. 2024 ($1,493 Mil) to Mar. 2025 ($1,492 Mil).

Astellas Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Astellas Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Accounts Payable & Accrued Expense Chart

Astellas Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1,225.14

1,375.70

1,087.60

1,493.19

1,491.97

Astellas Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1,493.19	1,284.89	1,379.55	1,601.87	1,491.97

Astellas Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.